Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
State University of New York at Buffalo
ClinicalTrials.gov Identifier:
NCT00123123
First received: July 21, 2005
Last updated: August 12, 2010
Last verified: August 2010
Results First Received: August 12, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Condition: Pneumonia
Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%)
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited from 1 March, 2004 until 30 November, 2007. Subjects were recruited from patients admitted to the ICU of the Erie County Medical Center (ECMC) who were mechanically ventilated. This ICU provides trauma, burn care, and rehabilitation and is an affiliated teaching facility for the State University of New York at Buffalo.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Vehicle control twice a day (oral rinse)
Chlorhexidine/Placebo Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day
Chlorhexidine chlorhexidine 1 oz oral rinse twice a day

Participant Flow:   Overall Study
    Placebo     Chlorhexidine/Placebo     Chlorhexidine  
STARTED     59     58     58  
COMPLETED     59     58     58  
NOT COMPLETED     0     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Vehicle control twice a day (oral rinse)
Chlorhexidine/Placebo Chlorhexidine oral rinse 1 oz once a day/placebo oral rinse once a day
Chlorhexidine chlorhexidine 1 oz oral rinse twice a day
Total Total of all reporting groups

Baseline Measures
    Placebo     Chlorhexidine/Placebo     Chlorhexidine     Total  
Number of Participants  
[units: participants]
  59     58     58     175  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     59     58     58     175  
>=65 years     0     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  50.0  ± 22.5     44.8  ± 19.9     47.6  ± 19.1     48.0  ± 20.8  
Gender  
[units: participants]
       
Female     23     15     14     52  
Male     36     43     44     123  
Region of Enrollment  
[units: participants]
       
United States     59     58     58     175  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours   [ Time Frame: Every 48 hours until discharge ]

2.  Secondary:   Clinical Pulmonary Infection Score (CPIS) at 48 Hours   [ Time Frame: 48 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Frank A. Scannapieco
Organization: University at Buffalo
phone: 716-829-3373
e-mail: fas1@buffalo.edu


Publications of Results:

Responsible Party: Frank A Scannapieco, DMD, Ph.D, University of Buffalo
ClinicalTrials.gov Identifier: NCT00123123     History of Changes
Other Study ID Numbers: NIDCR-14685, R01DE014685, 1R01-DE-14685-1A2
Study First Received: July 21, 2005
Results First Received: August 12, 2010
Last Updated: August 12, 2010
Health Authority: United States: Federal Government